{"id":739293,"date":"2023-03-10T19:48:24","date_gmt":"2023-03-11T00:48:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/"},"modified":"2023-03-10T19:48:24","modified_gmt":"2023-03-11T00:48:24","slug":"immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/","title":{"rendered":"Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank"},"content":{"rendered":"
\n

LOS ANGELES, March 10, 2023 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (\u201cImmixBio\u201d, \u201cCompany\u201d, \u201cWe\u201d or \u201cUs\u201d), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)\u2122 targeting oncology and immuno-dysregulated diseases, today confirms that neither ImmixBio, nor any of its subsidiaries, have any exposure to Silicon Valley Bank (\u201cSVB\u201d) or Silvergate Bank.<\/p>\n

\n About Immix Biopharma, Inc.<\/strong>
\n
Immix Biopharma, Inc. (ImmixBio\u2122) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)\u2122 targeting oncology and immuno-dysregulated diseases. Our proprietary SMARxT Tissue-Specific\u2122 Platform produces drug candidates that circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all 3 components of the tumor micro-environment (TME). We believe ImmixBio\u2019s TME Normalization\u2122 technology severs the lifelines between the tumor and its metabolic and structural support. Learn more at www.immixbio.com<\/u><\/a><\/p>\n

\n Investor Contact<\/b>
\n
Suzanne Messere
Stern Investor Relations
Suzanne.Messere@sternir.com<\/u><\/a><\/p>\n

\n Company Contact<\/b>
\n
\n
\n irteam@immixbio.com<\/u>
\n <\/a> \u00a0\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

LOS ANGELES, March 10, 2023 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (\u201cImmixBio\u201d, \u201cCompany\u201d, \u201cWe\u201d or \u201cUs\u201d), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)\u2122 targeting oncology and immuno-dysregulated diseases, today confirms that neither ImmixBio, nor any of its subsidiaries, have any exposure to Silicon Valley Bank (\u201cSVB\u201d) or Silvergate Bank. About Immix Biopharma, Inc. Immix Biopharma, Inc. (ImmixBio\u2122) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)\u2122 targeting oncology and immuno-dysregulated diseases. Our proprietary SMARxT Tissue-Specific\u2122 Platform produces drug candidates that circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all 3 components of the tumor micro-environment (TME). We believe ImmixBio\u2019s TME Normalization\u2122 technology severs the lifelines between the tumor … <\/p>\n

Continue reading “Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-739293","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImmix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LOS ANGELES, March 10, 2023 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (\u201cImmixBio\u201d, \u201cCompany\u201d, \u201cWe\u201d or \u201cUs\u201d), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)\u2122 targeting oncology and immuno-dysregulated diseases, today confirms that neither ImmixBio, nor any of its subsidiaries, have any exposure to Silicon Valley Bank (\u201cSVB\u201d) or Silvergate Bank. About Immix Biopharma, Inc. Immix Biopharma, Inc. (ImmixBio\u2122) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)\u2122 targeting oncology and immuno-dysregulated diseases. Our proprietary SMARxT Tissue-Specific\u2122 Platform produces drug candidates that circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all 3 components of the tumor micro-environment (TME). We believe ImmixBio\u2019s TME Normalization\u2122 technology severs the lifelines between the tumor … Continue reading "Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-11T00:48:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NjM0MiM1NDU2NDg2IzUwMDA5ODEwNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank\",\"datePublished\":\"2023-03-11T00:48:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\\\/\"},\"wordCount\":157,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NjM0MiM1NDU2NDg2IzUwMDA5ODEwNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\\\/\",\"name\":\"Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NjM0MiM1NDU2NDg2IzUwMDA5ODEwNA==\",\"datePublished\":\"2023-03-11T00:48:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NjM0MiM1NDU2NDg2IzUwMDA5ODEwNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NjM0MiM1NDU2NDg2IzUwMDA5ODEwNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/","og_locale":"en_US","og_type":"article","og_title":"Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank - Market Newsdesk","og_description":"LOS ANGELES, March 10, 2023 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (\u201cImmixBio\u201d, \u201cCompany\u201d, \u201cWe\u201d or \u201cUs\u201d), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)\u2122 targeting oncology and immuno-dysregulated diseases, today confirms that neither ImmixBio, nor any of its subsidiaries, have any exposure to Silicon Valley Bank (\u201cSVB\u201d) or Silvergate Bank. About Immix Biopharma, Inc. Immix Biopharma, Inc. (ImmixBio\u2122) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)\u2122 targeting oncology and immuno-dysregulated diseases. Our proprietary SMARxT Tissue-Specific\u2122 Platform produces drug candidates that circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all 3 components of the tumor micro-environment (TME). We believe ImmixBio\u2019s TME Normalization\u2122 technology severs the lifelines between the tumor … Continue reading \"Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-11T00:48:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NjM0MiM1NDU2NDg2IzUwMDA5ODEwNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank","datePublished":"2023-03-11T00:48:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/"},"wordCount":157,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NjM0MiM1NDU2NDg2IzUwMDA5ODEwNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/","name":"Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NjM0MiM1NDU2NDg2IzUwMDA5ODEwNA==","datePublished":"2023-03-11T00:48:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NjM0MiM1NDU2NDg2IzUwMDA5ODEwNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NjM0MiM1NDU2NDg2IzUwMDA5ODEwNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-confirms-no-exposure-to-silicon-valley-bank-or-silvergate-bank\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/739293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=739293"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/739293\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=739293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=739293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=739293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}